| Elevated plasma levels of CXCL16 in severe COVID-19 patients.Cytokine | PMID 35121493PMC8801318 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.Lancet Respir Med | PMID 35123660PMC8813065 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.Gynecol Oncol | PMID 35177279无 PMCID | 2022-Apr | 0.95 | Study is a Phase III randomized oncology trial with a drug intervention, but lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Primary endpoint is HPV clearance, a binary outcome. | 待处理 |
| XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).Cancer Commun (Lond) | PMID 35212487PMC9017757 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.Eur J Cancer | PMID 35220182无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.Lancet Oncol | PMID 35240053无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.ESMO Open | PMID 35247871PMC9058904 | 2022-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Haematol | PMID 35271808PMC8960285 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.Lung Cancer | PMID 35278766无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 35279270PMC8960282 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.ESMO Open | PMID 35279527PMC9161394 | 2022-Apr | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35298906无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.EBioMedicine | PMID 35306340PMC8933829 | 2022-Apr | 0.75 | The study is a secondary analysis of circulating tumor DNA and minimal residual disease biomarkers within a phase II/III randomized trial of rectal cancer. While it is oncology, human, randomized, phase-definitive, and reports a time-to-event endpoint (HR for recurrence), it lacks a specified drug-containing intervention (the analysis focuses on biomarker methods, not the trial's therapeutic arms). The report is a secondary biomarker analysis, not the primary trial result. | 待处理 |
| Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.ESMO Open | PMID 35334418PMC9058905 | 2022-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.ESMO Open | PMID 35344750PMC9058866 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.Lancet Haematol | PMID 35358441PMC8969057 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.J Am Soc Nephrol | PMID 35361724PMC8970450 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.CNS Drugs | PMID 35380374PMC8994715 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.J Immunother Cancer | PMID 35383114PMC8983994 | 2022-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.ESMO Open | PMID 35397432PMC9058903 | 2022-Apr | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial.Clin Ther | PMID 35410753无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.RMD Open | PMID 35428697PMC9014060 | 2022-Apr | 0.95 | The record is excluded because it is not an oncology study and lacks a time-to-event efficacy endpoint as required. | 待处理 |
| The Journeying through Dementia psychosocial intervention versus usual care study: a single-blind, parallel group, phase 3 trial.Lancet Healthy Longev | PMID 36098301无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.Eur Heart J | PMID 34405875PMC8970984 | 2022-Mar-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.J Antimicrob Chemother | PMID 35022730PMC9432134 | 2022-Mar-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus.J Antimicrob Chemother | PMID 35045168PMC9126070 | 2022-Mar-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes.BMC Med | PMID 35346165PMC8962078 | 2022-Mar-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.Arthritis Res Ther | PMID 35351194PMC8966257 | 2022-Mar-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.Vaccine | PMID 35232596无 PMCID | 2022-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.N Engl J Med | PMID 35179323PMC9844551 | 2022-Mar-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.N Engl J Med | PMID 35320642PMC7612678 | 2022-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.N Engl J Med | PMID 35320644无 PMCID | 2022-Mar-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).Sci Rep | PMID 35332216PMC8948251 | 2022-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.J Korean Med Sci | PMID 35315603PMC8938614 | 2022-Mar-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.J Clin Oncol | PMID 35007153PMC8937015 | 2022-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durability of three types of dual active ingredient long-lasting insecticidal net compared to a pyrethroid-only LLIN in Tanzania: methodology for a prospective cohort study nested in a cluster randomized controlled trial.Malar J | PMID 35305667PMC8934498 | 2022-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.N Engl J Med | PMID 35294811无 PMCID | 2022-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys | PMID 34808255无 PMCID | 2022-Mar-15 | 0.85 | The study is a Phase III randomized trial in oncology with a drug intervention, but the primary endpoint is change in patient-reported oral mucositis symptom scores over time, not a time-to-event efficacy endpoint. Secondary endpoints also focus on quality of life, opioid use, and safety. No time-to-event outcome (e.g., OS, PFS, DFS) or associated analysis (Kaplan-Meier, HR) is reported. | 待处理 |
| Efficacy and Safety of TJP-008 Compared to 2 L PEG with Ascorbate in Colon Cleansing: A Randomized Phase 3 Trial.Gut Liver | PMID 34810296PMC8924813 | 2022-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.Am J Respir Crit Care Med | PMID 34851799无 PMCID | 2022-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.Antimicrob Agents Chemother | PMID 34978890PMC8923183 | 2022-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.Acta Derm Venereol | PMID 35170742PMC9574691 | 2022-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.Antimicrob Agents Chemother | PMID 35191746PMC8923168 | 2022-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.Cancer Cell | PMID 35245446无 PMCID | 2022-Mar-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.BMC Infect Dis | PMID 35279081PMC8918293 | 2022-Mar-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.J Clin Oncol | PMID 34928708PMC8906451 | 2022-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.N Engl J Med | PMID 35263518无 PMCID | 2022-Mar-10 | 0.95 | The record reports a Phase 3 randomized trial in oncology with a drug-containing intervention (radioiodine). However, the primary endpoint is the proportion of patients without events at a fixed time (3 years), not a time-to-event analysis (Kaplan-Meier, HR, TTP, etc.) as required by the adjudication criteria. Therefore, it is ineligible. | 待处理 |
| Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.N Engl J Med | PMID 35263519无 PMCID | 2022-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.Rev Cardiovasc Med | PMID 35345262无 PMCID | 2022-Mar-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.J Natl Cancer Inst | PMID 34850043PMC8902441 | 2022-Mar-08 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |